(Q37994720)

English

The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels

scientific article published on 16 March 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

author name string

Neil Brickel

1

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Paul Gandhi

2

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Kevan VanLandingham

3

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Janet Hammond

4

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Sarah DeRossett

5

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

publication date

16 March 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

53

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

606-612

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Urinary bladder contraction and relaxation: physiology and pathophysiology

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03441.X

21 January 2018

Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03441.X

21 January 2018

Voltage-gated K(+) channels sensitive to stromatoxin-1 regulate myogenic and neurogenic contractions of rat urinary bladder smooth muscle

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03441.X

21 January 2018

Crystalluria: a neglected aspect of urinary sediment analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03441.X

21 January 2018

Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03441.X

21 January 2018

New tricks for old dogs: KCNQ expression and role in smooth muscle

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03441.X

21 January 2018

Neuronal KCNQ potassium channels: physiology and role in disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03441.X

21 January 2018

Lower urinary tract symptoms and uroflowmetry in women with type 2 diabetes mellitus with and without bladder dysfunction.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03441.X

21 January 2018

Nervous system KV7 disorders: breakdown of a subthreshold brake

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03441.X

21 January 2018

Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03441.X

21 January 2018

Functional effects of the KCNQ modulators retigabine and XE991 in the rat urinary bladder.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03441.X

21 January 2018

D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03441.X

21 January 2018

The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03441.X

21 January 2018

Direct and indirect costs of nephrolithiasis in an employed population: opportunity for disease management?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03441.X

21 January 2018

Phenytoin- and carbamazepine-resistant spontaneous bursting in rat entorhinal cortex is blocked by retigabine in vitro.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03441.X

21 January 2018

Urodynamic effects of the K+ channel (KCNQ) opener retigabine in freely moving, conscious rats

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03441.X

21 January 2018

Metabolic syndrome components worsen lower urinary tract symptoms in women with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03441.X

21 January 2018

D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03441.X

21 January 2018

Increased propensity for calcium phosphate kidney stones with topiramate use.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03441.X

21 January 2018

Identifiers

10.1111/J.1528-1167.2012.03441.X

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37994720&oldid=1736561574"